-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's Saxagliptin tablets were approved for submission in the generic 4 categories.
On March 17, 2021, the drug approval document pending information is released -1
Data show that saxagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which can prolong endogenous glucagon-like peptide-1 (GLP) by inhibiting DPP-4.
Sales of terminal saxagliptin tablets in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
Saxagliptin tablets were developed by Bristol-Myers Squibb.
Up to now, there are 5 manufacturers of saxagliptin tablets, and Qilu Pharmaceutical is the fourth domestic manufacturer.
Source: official website of the State Food and Drug Administration, Mi Nei.